Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Drop in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 6,740,000 shares, a decline of 18.5% from the October 31st total of 8,270,000 shares. Currently, 9.2% of the company’s stock are sold short. Based on an average daily volume of 529,200 shares, the short-interest ratio is currently 12.7 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd raised its position in Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Invivyd in the third quarter worth approximately $27,000. Tidal Investments LLC bought a new stake in Invivyd in the first quarter valued at approximately $126,000. Finally, Marshall Wace LLP increased its position in Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Up 0.1 %

Shares of NASDAQ:IVVD traded up $0.00 during midday trading on Monday, hitting $0.70. The stock had a trading volume of 757,959 shares, compared to its average volume of 645,812. The company has a market capitalization of $83.68 million, a P/E ratio of -0.36 and a beta of 0.65. The company’s 50-day moving average price is $0.92 and its 200-day moving average price is $1.16. Invivyd has a fifty-two week low of $0.58 and a fifty-two week high of $5.20.

Analyst Ratings Changes

IVVD has been the subject of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Invivyd in a research report on Thursday, November 21st. HC Wainwright lowered their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.